The adverse reaction experienced by a participant in the Oxford and AstraZeneca coronavirus vaccine trial may not have been caused by the experimental vaccine itself, it’s been claimed.
The trial was halted on September 6 after a participant displayed an illness thought to be a rare spinal inflammatory disorder called transverse myelitis.
An information leaflet for participants has now indicated that the adverse reaction may not have occurred as a result of the jab.
The document said: “After independent review, these illnesses were either considered unlikely to be associated with the vaccine or there was insufficient evidence to say for certain that the illnesses were or were not related to the vaccine.”
The vaccine trials have now resumed in Britain, Brazil and South Africa, but have not started up again in the United States.
The University of Oxford and AstraZeneca are among the front runners in the race to deliver a jab.
Phase 1 of the Oxford trial demonstrated favourable results as scientists found their jab triggered a response that may offer a double defence against the virus.
However, most studies are halted at some phase, that’s why we have stringent testing to ensure it’s safe before reaching the population, and that’s for any medication and for anything that looks unusual the breaks should go on to see if there’s a connection to the drug and if not, then it resumes and it’s exemplary that they took the proper measures rather than cladding up data so that they could push something through.